摘要
Ovarian cancer(OC)is the deadliest gynecologic malignancy,with platinum-based chemotherapy,such as carboplatin,remaining the standard first-line treatment.However,resistance to carboplatin poses a major therapeutic challenge,and its mechanisms are not fully understood.
基金
supported by the US National Institutes of Health(No.1R01GM120156-01A1,R03CA223906-01,1R03CA283225-A1 to T.L.)
the Kay Yow Cancer Fund(V Foundation for Cancer Research)(USA)(No.4486242 to T.L.)
Showalter Scholar fund from Indiana University School of Medicine(USA)(No.2286263 to T.L.)
the Indiana University Melvin and Bren Simon Comprehensive Cancer Center(IUSCCC)fund(USA)(No.2987664 to T.L.).
